Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Contineum TherapeuticsCTNM -1.37%17 EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 941 Biotechnology companies, Contineum Therapeutics ranks worse than 106269.82% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Contineum Therapeutics EBITDA Margin % Related Terms
Contineum Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Contineum Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTNM vs FDMT, PRME, ARVN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Contineum Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Contineum Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Contineum Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Contineum Therapeutics (CTNM) has a EBITDA Margin % of 0.00% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Contineum Therapeutics and its competitors. Over the past decade, Contineum Therapeutics' EBITDA Margin % has ranged from 47.15 to 47.15. According to the industry distribution chart, Contineum Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry.
Is Contineum Therapeutics' EBITDA Margin % too high?
Contineum Therapeutics' current EBITDA Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 47.15 to a high of 47.15. Based on the distribution chart, Contineum Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' EBITDA Margin % compare to FDMT and PRME?
According to the Biotechnology industry distribution chart, Contineum Therapeutics ranks #999999 out of 941 companies for EBITDA Margin %. This places Contineum Therapeutics in the lower half of its industry. Historically, Contineum Therapeutics' own EBITDA Margin % has ranged from 47.15 to 47.15 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Contineum Therapeutics and its competitors. Contineum Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Contineum Therapeutics' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score
Get the complete analysis for CTNM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTNM has been successfully added to your 
